Harvard Bioscience Inc. reported second-quarter revenue of $22.7 million [1], representing an 11% increase year-over-year [1].
The results signal a recovery in demand for the company's Cellular-Molecular Technology and China-based operations, allowing executives to raise their full-year financial outlook.
During a conference call on Aug. 18, company management reported an adjusted gross margin of 57% [1] and adjusted EBITDA of $1.7 million [1]. The EBITDA figure marks an 11% increase over the previous year [1].
President and CEO Duke said the midpoint of the provided range is $21.8 million in revenue, which would represent six% growth over last year [3]. The company has now targeted full-year 2026 revenue growth between three% and five% [3].
Looking toward the second half of the year, CFO Frost said growth expectations for the third quarter are in the "mid-single digits" [3]. Frost said the fourth quarter would indicate growth of four% to six% as well [3].
For the full 2026 fiscal year, the company is targeting an adjusted gross margin between 57% and 59% [3]. These targets follow a period of fluctuating demand across its global markets, particularly within its specialized bioscience tool segments.
Management said the Q2 revenue growth was 10% when measured on a constant currency basis [1]. This distinction accounts for currency fluctuations that can impact international earnings reports.
“Harvard Bioscience reported second-quarter revenue of $22.7 million, representing an 11% increase year-over-year.”
The upward revision of full-year guidance suggests that Harvard Bioscience is seeing a stabilization in the life sciences tool market. By raising its revenue growth target to 3-5%, the company is betting on continued momentum in its Cellular-Molecular Technology division and a recovery in the Chinese market, both of which have been volatile in recent years.
